Skip to content
DataLookout
Menu

DUET-ADNCT06709014

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 71 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Final enrollment: 861 participants (planned 760)
  2. Notable Eligibility criteria expanded, about 40 words
    • Primary endpoints: details revised at 2 of 2 entries
    • Interventions: Placebo (Drug), buntanetap/posiphen (Drug) to Placebo (Drug), buntanetap/posiphen (Drug)
    • Site details revised at 7 of 78 sites
  3. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Trial sites reduced: 81 → 78 locations
    v69
  4. Minor Site details revised at 9 of 81 sitesv68
  5. Minor Site details revised at 8 of 81 sitesv67
Show 44 earlier versionsHide 44 earlier versions
  1. Minor Site details revised at 1 of 81 sitesv66
  2. Minor Study sites: 83 to 81v65
  3. Minor Site details revised at 1 of 83 sitesv64
  4. Minor Site details revised at 4 of 83 sitesv63
  5. Minor Site details revised at 4 of 83 sitesv62
  6. Minor Collaborators: 1 to 2v61
  7. Minor Site contacts updated at 1 of 83 sitesv60
  8. Notable Eligibility criteria revisedv59
  9. Minor Study sites: 84 to 83v57
  10. Minor Study sites revised (84)v56
  11. Minor Site contacts updated at 1 of 84 sitesv55
  12. Minor Site details revised at 6 of 84 sitesv54
  13. Minor Site details revised at 3 of 84 sitesv53
  14. Minor Site details revised at 1 of 84 sitesv52
  15. Minor Site details revised at 1 of 84 sitesv51
  16. Minor Study sites: 85 to 84v50
  17. Minor Site details revised at 2 of 85 sitesv49
  18. Minor Study sites: 86 to 85v48
  19. Minor Site details revised at 1 of 86 sitesv47
  20. Minor Site details revised at 1 of 86 sitesv46
  21. Minor Study sites: 85 to 86v45
  22. Minor Study sites: 81 to 85v44
  23. Notable Eligibility criteria expanded, about 27 words
    • Secondary endpoints shortened, about 23 words
    • Site details revised at 2 of 81 sites
    v43
  24. Minor Study sites: 79 to 81v42
  25. Minor Study sites: 78 to 79v41
  26. Minor Site details revised at 3 of 78 sitesv40
  27. Minor Study sites: 76 to 78v39
  28. Minor Study sites: 75 to 76v38
  29. Minor Study sites: 72 to 75v37
  30. Minor Site details revised at 2 of 72 sitesv36
  31. Minor Site details revised at 7 of 72 sitesv35
  32. Minor Study sites: 58 to 72v34
  33. Minor Study sites: 56 to 58v33
  34. Minor Study sites: 54 to 56v32
  35. Minor Study sites: 53 to 54v31
  36. Minor Study sites: 47 to 53v30
  37. Minor Site details revised at 1 of 47 sitesv29
  38. Minor Study sites: 45 to 47v28
  39. Minor Study sites: 42 to 45v27
  40. Minor Site details revised at 2 of 42 sitesv26
  41. Minor Study sites: 41 to 42v25
  42. Minor Study sites: 39 to 41v24
  43. Minor Study sites: 36 to 39v23
  44. Minor Study sites: 33 to 36v22
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Timeframe: From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Timeframe: From screening to 6-month readout, to end of treatment at 18 months.

Arms and interventions

buntanetapExperimental
PlaceboPlacebo comparator

Drugs: buntanetap/posiphen, Placebo

Sites

78 sites in 1 country